Tukysa
About Tucatinib or Tukysa
Tucatinib is a kinase inhibitor that is used in combination with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer, including those with brain metastases, who have previously received one or more anti-HER2-based regimens in the metastatic setting.
Strength
50 mg and 150 mg Tucatinib tablets
Recommended Dosage:
Oral administration of 300 mg twice a day, with or without meals. The recommended dosage for people with severe hepatic impairment is 200 mg orally twice a day.
Important: If patients experience any adverse reactions from the Tucatinib tablets, they must consult their treating doctor.
Warnings & Precautions
- Patients have experienced severe diarrhea, involving dehydration, acute renal damage, and death. As clinically indicated, administer anti-diarrheal medication. Depending on the severity, it is necessary to reduce or discontinue the Tucatinib tablets.
- Severe cases of hepatotoxicity have been reported. Monitor ALT, AST, and bilirubin levels before beginning Tukysa 150 mg or as prescribed by the consulting doctor, as well as every 3 weeks during treatment and as clinically required. Depending on the severity, reduce or discontinue the Tukysa tablets.
- Tukysa tablets have the potential to damage a fetus. It is necessary to inform female patients of the potential risk to a fetus and encourage them to utilize effective contraception.
Common Tucatinib Side Effects
- Diarrhea
- Palmar-plantar erythrodysesthesia
- Nausea
- Fatigue
- Hepatotoxicity
- Vomiting
- Stomatitis
- Reduced appetite
- Abdominal pain
- Headache
- Anemia
- Rashes
Storage and Handling
Store at a regulated room temperature of 20ºC to 25ºC, with excursions tolerated between 15ºC and 30ºC.
We follow a four-step process to procure the medicines:
- Enquiry about the medicines: You submit a request for information about the medications you require using our portal, and we process your data. Within 24 hours, a member of our Named Access Program Support will get in touch with you and provide you with all the assistance you need.
- Verification Process: As we assist patients in finding medications that are not yet approved and readily available in their home countries, Sansfro must confirm the availability and approval of the medicines they need. We also check the patient’s prescription and medical information.
- Sourcing the Medicine: After the verification process has been successfully completed, our staff will contact our vast network of suppliers to find your medicine. Following the process, our team gets the best rates of the medicines for you and ensures processing.
- Safe Delivery: We will set up the consignment’s safe delivery after the final quote is approved. Additionally, our logistics experts can help you track your consignment. The Named Access Program industry has a large number of unauthorized channels. To provide the medications safely and legally, we do so by adhering to the Standard Operating Procedures.
When importing medication, we will need the following documents from the patient:
- A valid prescription copy.
- An identity proof document.
- Details of the attending healthcare professional.
- A current address.
Once we have all these documents, the Sansfro team will initiate the application process for an import license. This license is essential to ensure that we can obtain the necessary medication once it receives government approval.
No news found.
About Sansfro
Sansfro is committed to bridging the healthcare gap. Our purpose is to bring hope and healing to patients suffering from rare diseases by linking them with life-saving treatments through our Named Patient Program. Join us in our quest for a better and healthier world.
Know More...FAQ'S
How does Tucatinib work?
Tukysa inhibits the HER2 protein, which promotes the proliferation of HER2-positive breast cancer cells.
Who can take Tukysa treatment?
Tucatinib is primarily given to patients with HER2-positive metastatic breast cancer who have already been treated with other HER2-targeted treatments.
How is the Tukysa tablet taken?
Tukysa is often administered orally as pills. Your consulting doctor will provide you with specific dosage instructions.
Are there any common Tucatinib side effects?
Tukysa’s most common adverse effects are diarrhea, nausea, vomiting, exhaustion, and headache. Patients must contact their consulting doctor if they experience any adverse side effects.
Can Tukysa be prescribed to all patients with HER2-positive breast cancer?
Tucatinib may not be appropriate for everyone. It is suitable for patients based on their medical history and current health situation, as determined by their consulting doctor.
How to Buy Tukysa online if it is not available offline?
Tukysa is a prescription medication that is rarely found both offline and online, except in the USA and Europe. Patients or their family members can get in touch with the Sansfro team for assistance with Tukysa. Sansfro can facilitate the import of this product either from the US or Europe.
What is the price of Tukysa in India?
Tukysa price in India depends on the product requirement and the country where the product is ordered. Request more details by reaching out to our Patient Support Team at (+91) 93157 05373 or help@sansfro.com
Dr Anchal Aryan
Medical counselor
Patient Stories
Word Wide Delivery:
India, Andorra, Argentina, Australia, Austria, Azerbaijan, Bahrain, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cyprus, Denmark, Dominican Republic, Estonia, Finland, France, Georgia, Germany, Ghana, Greece, Guatemala, Iraq, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kenya, Kuwait, Latvia, Lebanon, Libya, Lithuania, Malawi, Mexico, Montenegro, Nepal, Netherlands, New Zealand, Nigeria, Norway, Oman, Pakistan, Paraguay, Peru, Poland, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, Spain, Sri Lanka, Sweden, Switzerland, United Arab Emirates, United Kingdom, United States, Venezuela, Zimbabwe, Afghanistan, Albania, Algeria, American Samoa, Angola, Anguilla, Antarctica, etc.